Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Feb;26(2):119-126.
doi: 10.1002/pds.4083. Epub 2016 Aug 16.

The appropriateness and persistence of testosterone replacement therapy in Ontario

Diana Martins  1 , Zhan Yao  1 , Mina Tadrous  1   2   3 , Baiju R Shah  1   4   5   6 , David N Juurlink  1   4   7   5   6 , Muhammad M Mamdani  1   2   4   5   3   8 , Tara Gomes  1   2   5   3 ; Ontario Drug Policy Research Network
Affiliations

The appropriateness and persistence of testosterone replacement therapy in Ontario

Diana Martins et al. Pharmacoepidemiol Drug Saf. 2017 Feb.

Abstract

Purpose: To examine the concordance between testosterone replacement therapy (TRT) use and established reimbursement criteria, as well as compare the persistence of use among available formulations (injectable, oral, topical gel, transdermal patch) among elderly men in Ontario, Canada.

Methods: We conducted a retrospective cohort study of men aged 66 years or older in Ontario newly treated with testosterone between 1 January 2009 and 31 December 2012 using linked health administrative data. Continuous use was defined on the basis of prescription refills issued within 180 days of the preceding prescription. We studied men who received at least two consecutive TRT prescriptions. We estimated the prevalence of hypogonadism, human immunodeficiency virus, specialist visits and lab tests for serum testosterone prior to initiation of TRT to investigate concordance with prescribing criteria. We also performed a Kaplan-Meier analysis to test for differences in the median time to discontinuation among formulations.

Results: Among the 4797 men who received at least two TRT prescriptions, only 38.7% met the reimbursement criteria for use prior to initiating therapy. The median time to discontinuation differed significantly among formulations and was longest among recipients of oral TRT products (383 days), and lower for recipients of topical gels (319 days), injectable (283 days) and transdermal patches (160 days; Log-rank test p < 0.001).

Conclusions: A large proportion of older men in Ontario do not appear to meet reimbursement criteria prior to commencing therapy, and many discontinue TRT within a year of initiation. Copyright © 2016 John Wiley & Sons, Ltd.

Keywords: Hormone Replacement Therapy; hypogonadism; medication adherence; pharmacoepidemiology; testosterone.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

Publication types

LinkOut - more resources